Proteomic Signals in HER2 Metastasis

Evidence

This single-study explainer covers an integrated multi-omics investigation of stromal–tumor-initiating-cell interactions in HER2-positive breast cancer. The reported design combined spatial transcriptomics, metabolomics, spatial in situ analysis, and proteomics with exosomal microRNA high-throughput sequencing, single-nucleus RNA sequencing, in vitro experiments, murine breast cancer models, parabiosis assays, clinical-sample analysis, and validation in public single-cell RNA-sequencing datasets. The clinical samples were derived from consecutive patients with confirmed HER2-positive breast cancer admitted to Shanghai General Hospital between January 2023 and March 2025. pmid:42718887

For single-nucleus RNA sequencing, the investigators extracted exosomes and performed sequencing from tumor tissues of 4 patients with HER2-positive breast cancer. After quality control, 2,294 single nuclei were retained for downstream analysis, with an average of 36,601 genes detected per nucleus. Unsupervised clustering and UMAP visualization identified eight cell types. These quantities describe the sequencing component of the study; they are not a measure of clinical benefit or diagnostic performance. pmid:42718887

Integrated analyses identified PROM1-positive, SMAD5-positive tumor-initiating cells and interactions with ADIPOQ-positive, NOTCH4-positive adipocytes and DCN-positive, TM4SF1-positive fibroblasts. The study reports that the two stromal subpopulations mediated COPA-dependent EGFR activation in the PROM1-positive, SMAD5-positive cells. This was reported to trigger an EGFR-SMAD5-CYP3A4 axis associated with partial epithelial-mesenchymal transition and metastasis. Proteomics was one component of the integrated strategy used to identify molecular interactions in the tumor microenvironment. pmid:42718887

The investigators also reported that stroma-secreted exosomal miR-671-3p down-regulated Claudin1 in PROM1-positive, SMAD5-positive cells. In the proposed model, this promoted evolution into PROM1-positive, SMAD5-positive, Claudin1-negative subpopulations described as having enhanced stemness and metastatic potential. In vivo experiments reportedly showed that the two stromal subpopulations markedly promoted pulmonary metastasis, while the three identified subpopulations preferentially accumulated in primary tumors, lymph nodes, and pulmonary metastatic lesions in tumor-bearing mice. pmid:42718887

Clinical-sample analysis linked aggregation of the three subpopulations, termed a “trinity niche” by the authors, with HER2 positivity, high malignancy, lymph-node metastasis, pulmonary metastasis, and poor prognosis. The source describes these as associations and a prognosis-related observation. It does not turn the reported molecular relationships or experimental results into a validated clinical test, treatment effect, or patient-level conclusion. pmid:42718887

The reported statistical workflow included one-way ANOVA for cytokine comparisons across pathological groups and used a two-tailed P value below 0.05 as the study’s stated statistical-significance threshold. No effect estimate, confidence interval, comparator-specific denominator, or result-level P value for the central stromal–tumor-initiating-cell findings is presented in the provided extracted findings. pmid:42718887

Analysis — Protein-Centered Metastatic Crosstalk

The central proteomics-relevant contribution is the placement of protein and pathway signals within a spatially organized metastasis model rather than the reporting of a standalone protein biomarker result. PROM1 and SMAD5 define the tumor-initiating population of interest, while ADIPOQ, NOTCH4, DCN, and TM4SF1 distinguish the reported stromal partners. COPA, EGFR, SMAD5, CYP3A4, and Claudin1 then provide a proposed molecular route connecting stromal interaction to partial epithelial-mesenchymal transition, altered cell state, and metastatic behavior. This framing is mechanistically coherent within the study’s integrated dataset because spatial, transcriptomic, exosomal, in vitro, and in vivo approaches were all reported. However, the findings should be read as evidence from one multifaceted research program, not as independent confirmation that any individual protein is clinically actionable. Statistical significance, where a threshold is stated, is not itself evidence of clinical significance. pmid:42718887

Limitations

The study’s breadth supports hypothesis generation across cell states, spatial context, and experimental models, but the supplied material does not provide a separately reported proteomics-only quantitative result. Accordingly, the available evidence cannot distinguish the contribution of proteomics from the other integrated assays in the reported interaction discoveries. pmid:42718887

The clinical sequencing component involved tumor tissues from 4 patients, whereas the broader work also used murine models, parabiosis assays, clinical samples, and two public single-cell datasets. This mixed evidence base is valuable for examining mechanism, yet the supplied findings do not provide the effect sizes, confidence intervals, or result-level P values needed to quantify the magnitude or precision of the principal clinical associations. pmid:42718887

The reported associations with HER2 positivity, malignancy, metastasis, and prognosis do not establish causation in patients. Likewise, murine pulmonary-metastasis findings and in vitro interaction experiments do not by themselves establish clinical utility for a protein measurement, a prognostic classifier, or a therapeutic intervention. pmid:42718887